 "Hepatitis C Virus")
Hyderabad-based Hetero Drugs announced today that it was the first company in India to receive the approval for the fixed-dose anti Hepatitis-C combination drug Ledipasvir-Sofosbuvir from the Drug Controller General of India(DCGI).
In September last year, Hetero signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and market chronic hepatitis medicines.
Hetero is all set to launch the product for the Indian patients. The product will be available under the brand name Ledisof in India, according to the company.
"We have been the front runners in launching the generic Sofosbuvir in several countries. We are happy to extend the fixed-dose combination therapy to Indian patients, which is much more effective than Sofosbuvir," B P S Reddy, chairman and managing director of Hetero group said.
